Sciclone Pharmaceuticals Patent Grants

Alpha thymosin peptides as vaccine enhancers

Granted: May 6, 2014
Patent Number: 8716012
The present invention provides methods of vaccination as well as pharmaceutical combinations and kits for enhancing vaccine effectiveness, including for immunodeficient or immunecompromised patients, including non-responders and low-responders to vaccination. As disclosed herein, the invention relates to administering a vaccine and a regimen of thymosin alpha peptide so as to provide higher antibody titers, speed the development of such antibody titers, and/or to provide for a longer…

Treatment of infections with alpha thymosin peptides

Granted: March 5, 2013
Patent Number: 8389680
A method for treating a human infected with Aspergillus by using thymosin alpha 1 as an immuno-stimulator in activating dendritic cells. The method is particularly useful in preventing an infection by Aspergillus in an immuno-compromised host being treated with a bone marrow transplantation.

Treatment of infections with alpha thymosin peptides

Granted: June 26, 2012
Patent Number: 8207294
A method for treating a human infected with Aspergillus by using thymosin alpha 1 as an immuno-stimulator in activating dendritic cells. The method is particularly useful in preventing an infection by Aspergillus in an immuno-compromised host being treated with a bone marrow transplantation.

Treatment or prevention of hemorrhagic viral infections with immunomodulator compounds

Granted: June 5, 2012
Patent Number: 8193152
An immunomodulatory compound is administered to a patient having, or at risk of a hemorrhagic viral infection.

Treatment of melanoma

Granted: April 24, 2012
Patent Number: 8163702
An immunomodulatory compound is administered to treat, prevent, inhibit, or reduce melanoma in a subject.

Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma

Granted: October 4, 2011
Patent Number: 8029799
It is described the use of thymosin alpha in combination with dacarbazine and optionally with Interferon alpha, for preparing a medicament for the treatment of malignant melanoma on stage IV characterized by distant unresectable metastases.

Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma

Granted: September 13, 2011
Patent Number: 8017129
It is described the use of thymosin alpha in combination with dacarbazine and optionally with Interferon alpha, for preparing a medicament for the treatment of malignant melanoma on stage IV characterized by distant unresectable metastases.

Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa

Granted: March 15, 2011
Patent Number: 7906486
An immunomodulatory compound is utilized to treat mucosa disease.

Methods of protecting against radiation damage using alpha thymosin

Granted: March 1, 2011
Patent Number: 7897567
Damage to cells and/or a subject caused by radiation is treated or prevented by administration of an alpha thymosin peptide.

Thymosin alpha 1 peptide/polymer conjugates

Granted: November 20, 2007
Patent Number: 7297676
A pharmaceutical composition includes a physiologically active conjugate including a Thymosin alpha 1 (TA1) peptide conjugated to a material which increases half-life of the TA1 peptide in serum of a patient when the conjugate is administered to a patient. The material may be a substantially non-antigenic polymer. In a method of the invention, the substantially non-antigenic polymer is conjugated to a TA1 peptide. Compositions according to the invention are administered to patients in…

Treatment of hepatitis C with thymosin and peptide combination therapy

Granted: April 24, 2007
Patent Number: 7208167
A method and pharmaceutical combination for treating hepatitis C by administering to a hepatitis C patient an effective amount of at least one alpha thymosin peptide, in combination with administration to the hepatitis C patient of an effective amount of at least one interferon, and optionally in combination with administration of at least one antiviral agent such as ribavirin.

Treatment of tuberculosis using immunomodulator compounds

Granted: February 6, 2007
Patent Number: 7173013
Tuberculosis in an animal is treated by administration of a therapeutically effective amount of an immunomodulator of formula A. In formula (A), n is 1 or 2, R is hydrogen, acyl, alkyl or a peptide fragment, and X is an aromatic or heterocyclic amino acid or a derivative. The animal may be a mammal such as a human

Combination therapy method for treating chronic hepatitis B

Granted: December 17, 2002
Patent Number: 6495521
The present invention is aimed at augmenting the success rate of using thymosin in treatment of chronic hepatitis B, by employing a combination therapy using thymosin with antiviral agents which are effective in inhibiting DNA synthesis or DNA polymerase during replication of the hepatitis B virus.

Method of reducing side effects of chemotherapy in cancer patients

Granted: October 8, 2002
Patent Number: 6462017
A method for reducing the severity of chemotherapy side effects in cancer patients by administering thymosin &agr;1 in conjunction with the administration of a chemotherapy agent to the patient. As a result of the reduction of post-chemotherapy side effects, patients experience an increase in the quality of life.

Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir

Granted: September 11, 2001
Patent Number: 6288033
A method of treatment of hepatitis B virus (HBV) infection in a patient by administering to the patient a drug regimen including an antiviral-effective amount of thymosin alpha 1 (T&agr;1), an antiviral-effective amount of lamivudine, and optionally an antiviral-effective amount of famciclovir is disclosed.

Analogs of thymosin &agr;1

Granted: July 17, 2001
Patent Number: 6262230
Compounds of the formula: X-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-  (I) Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Z wherein X is an acetyl or pyroglutamyl group and Z is —NH2, -Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-Pro-NH2, -Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-Gly-NH2, or -Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn with the proviso that when X is a pyroglutamyl group, Z is -Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn, and when X is an acetyl group, Z…

Combination therapy method for treating chronic hepatitis B

Granted: March 13, 2001
Patent Number: 6200952
The present invention is aimed at augmenting the success rate of using thymosin in treatment of chronic hepatitis B, by employing a combination therapy using thymosin with antiviral agents which are effective in inhibiting DNA synthesis or DNA polymerase during replication of the hepatitis B virus.

Method of treating hepatitis C in non-responders to interferon treatment

Granted: December 14, 1999
Patent Number: 6001799
A method of treating Hepatitis C by administering an immune system-potentiating dose of at least one Thymosin or system-potentiating Thymosin fragment to a mammal infected with Hepatitis C virus, which Hepatitis C infection in the mammal is non-responsive to treatment with interferon alone.

Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir

Granted: August 17, 1999
Patent Number: 5939423
Treatment of hepatitis B virus (HBV) infection in a patient by administering to the patient a drug regimen including an antiviral-effective amount of thymosin alpha 1 (T.alpha.1) and an antiviral-effective amount of famciclovir.

Composition and method of treating hepatitis C

Granted: December 15, 1998
Patent Number: 5849696
Compositions and methods of use for treating hepatitis C virus-infected mammals are disclosed. The compositions include one or more thymosins alone or in combination with one or more interferons. Methods of treatment include use of thymosins alone, or together, or sequentially with interferon.